Recently, it has been found that human hepatocellular carcinoma (HCC) cell lines secrete fairly amounts of TGF-β. Considering the possible negative effects of TGF-β on the immunotherapeutic regimen, in which we intend to induce LAK cells endogenously by systemic IL-2 infusion, we focused on the analysis of immunosuppressive effects of TGF-β on the generation of human LAK cells. The results were as follows:
(1) TGF-β inhibited LAK cell generation
in vitro in a dose-dependent manner at concentration ranging from 120ng/m
l. LAK cells, once fully activated, became resistant to the suppressive effects of TGF-β.
(2) Inhibitory effect was most prominent when TGF-β was added 24 hours prior to IL-2 addition. On the contrary, when TGF-β was added 24 hours later than IL-2, TGF-β could not exert enough suppression.
(3) Flow cytometric analysis revealed the differential effects of TGF-β on the expression of IL-2 receptor, α and β chain. In contrast to the marked suppression of membrane-bound IL-2 R α chain, β chain was not down-regulated.
(4) Measurement of soluble IL-2 R level, corresponding to the shedded form of IL-2 R α chain, showed the inhibition of soluble IL-2 R secretion by TGF-β, indicating the overall suppression of IL-2 R α chain production.
All these results suggest that manipulation of the production or the effects of TGF-β derived from malignant cells might be an important aspect for successful immunotherapy.
View full abstract